Skip to main content

Botulinum Toxin Market Size [2027] | is Projected to Reach USD 7.71 Billion, Exhibiting a CAGR of 7.5%

Key Players Covered in the Botulinum Toxin Market Research Report Are Revance Therapeutics, Inc. (California, U.S.), Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China), USWM, LLC. (Kentucky, U.S.), Merz Pharma (Frankfurt, Germany), HUGEL, Inc. (Seoul, Republic of Korea), Galderma (Lausanne, Switzerland), Medytox (Cheongju-si, South Korea), Allergan (Dublin, Ireland) and other key market players.

Pune, India, Oct. 26, 2021 (GLOBE NEWSWIRE) — The global botulinum toxin market size is projected to reach USD 7.71 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. Proven effectiveness of botox in treating chronic pain disorders will be a major factor propelling the growth of this market, states Fortune Business Insights™ in its report, titled “Botulinum Toxin Market Size, Share & COVID-19 Impact Analysis, By Application {Therapeutic (Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Belpharospasm, Others) and Aesthetics}; By Type (Botulinum Toxin A and Botulinum Toxin B); By End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others); and Regional Forecast, 2020-2027”.

A highly potent neurotoxin, botulinum toxin has been found to be effective in producing a therapeutic effect on the body, according to a study published in Portland Press. Its potential for treating complex chronic pain conditions led the US Food and Drug Administration (FDA) to green light botulinum toxin as a treatment option for glabellar lines, blepharospasm, and cervical dystonia. Moreover, recent evidence has also shown that this protein is equally effective managing chronic migraine. A study conducted by researchers at the University Hospital Rangueil, Toulouse, France found that botulinum toxin injections are effective in reducing the frequency of chronic migraine headaches. Thus, widening applicability of this toxin in treating chronic pain disorders will fuel the growth of this market in the upcoming years.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/botulinum-toxin-market-100996

According to the report, the global market value stood at USD 4.83 billion in 2019. The report offers the following:

  • Comprehensive evaluation of all market segments;
  • Detailed analysis of the market drivers, trends, restraints, and opportunities;
  • Actionable insights into the regional dynamics shaping the market; and
  • Careful examination of the key market players’ profiles and strategies.


Report Scope & Segmentation

Report CoverageDetails
Forecast Period2020 to 2027
Forecast Period 2020 to 2027 CAGR7.5%
2027 Value ProjectionUSD 7.71 billion
Base Year2019
Market Size in 2019USD 4.83 billion
Historical Data for2016 to 2018
No. of Pages151
Segments coveredBy Material, By Product, By End User, Specialty & Dermatology Clinics
Growth DriversHigh Demand for Cosmetic Procedures to Fuel the Market in North America
Cancellation of Elective Procedures to Stall Market Growth
Strong Support from Regulatory Authorities for Novel Treatments to Energize Competition


Market Restraint

Cancellation of Elective Procedures to Stall Market Growth

The COVID-19 pandemic is set to deliver a critical setback to the botulinum toxin market growth, with hospitals around the world deciding to defer planned elective surgeries and focus on treating coronavirus patients. The CovidSurg Collaborative, a research initiative led by the University of Birmingham in the UK to assess the impact of the pandemic on surgeries, estimates that approximately 28 million planned surgeries worldwide are likely to get cancelled owing to the massive disruptions in healthcare services.

Another study conducted by researchers at the Johns Hopkins University in the US found that even if elective surgeries resumed in June 2020, health facilities would take over a year to perform 90% of the procedures planned in the pre-pandemic period. Cosmetic procedures involving botox are considered non-essential and are most likely to get delayed or cancelled, resulting in steep losses for pharmaceutical companies as well as specialty clinics and facilities. 


Click here to get the short-term and long-term impacts of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996


Regional Insights

High Demand for Cosmetic Procedures to Fuel the Market in North America

North America, with a market size of USD 3.19 billion in 2019, is expected to command the botulinum toxin market share during the forecast period owing to the high number of minimally-invasive cosmetic procedures being performed in the region. For example, the American Society of Plastic Surgeons estimates that around 15.9 million cosmetic procedures were performed in the US in 2018.

Europe is anticipated to emerge as the second-largest region in this market on account of increasing investments in research & development activities by pharmaceutical companies in the region. The market in Asia Pacific, on the other hand, is expected to present lucrative opportunities owing to the rising disposable incomes in the region, which is creating demand for advanced cosmetic and therapeutic procedures and treatments.

Competitive Landscape

Strong Support from Regulatory Authorities for Novel Treatments to Energize Competition

Backed by a favorable regulatory climate, key players in this market are heavily investing to enhance their R&D capabilities to come out with innovative botulinum toxin-based treatments for chronic conditions. In addition to this, companies are also expanding their regional and global presence through strategic collaborations.


Quick Buy –  Botulinum Toxin Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100996


Industry Developments:

  • July 2020: The US FDA approved Allergan’s supplemental Biologics License Application for extending the use of BOTOX to treat spasticity in pediatric patients aged 2 years and above. The application also includes the use of BOTOX for treating children with lower limb spasticity caused by cerebral palsy.
  • June 2020: Merz Pharmaceuticals and Teijin Pharma Limited announced that Japan’s Ministry of Health, Labor, and Welfare granted Teijin the right to market Xeomin® (incobotulinumtoxinA) developed by Merz. The treatment is designed to treat upper limb spasticity with intramuscular injections of varying doses.


List of Key Companies Profiled in this Market Report:

  • Revance Therapeutics, Inc. (California, U.S.)
  • Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China)
  • USWM, LLC. (Kentucky, U.S.)
  • Merz Pharma (Frankfurt, Germany)
  • HUGEL, Inc. (Seoul, Republic of Korea)
  • Galderma (Lausanne, Switzerland)
  • Medytox (Cheongju-si, South Korea)
  • Allergan (Dublin, Ireland)

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/botulinum-toxin-market-100996


Global Botulinum Toxin Market Segmentation

By Application

  • Therapeutics
  • Chronic Migraine
  • Spasticity
  • Overactive Bladder
  • Cervical Dystonia
  • Blepharospasm
  • Others
  • Aesthetics

By End User

  • Specialty and Dermatology Clinics
  • Hospitals and Clinics
  • Others

By Type

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/botulinum-toxin-market-9190

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.